Status:
TERMINATED
Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer
Lead Sponsor:
Geisinger Clinic
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Head and Neck Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Phase II Study of Maintenance Tarceva (Erlotinib) in patients with locally advanced Head and Neck Cancer after treatment with curative intent
Eligibility Criteria
Inclusion
- Stage III, IV SCCHN
- Completed curative treatment
Exclusion
- Prior chemotherapy or radiotherapy
- Recurrent disease
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT00750555
Start Date
September 1 2008
End Date
December 1 2009
Last Update
February 26 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Geisinger Health System
Danville, Pennsylvania, United States, 17822